Optic Neuritis Therapeutics Market Size in the 7MM was ~USD 3 Million in 2024 and It is projected to grow at a CAGR of 1.4% by 2034, estimates DelveInsight

DelveInsight's "Optic Neuritis Market Insight, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of Optic Neuritis, historical and forecasted epidemiology as well as the Optic Neuritis market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Unlock detailed insights into the Optic Neuritis Market by downloading the comprehensive report from DelveInsight @ Optic Neuritis Therapeutics Market- https://www.delveinsight.com/sample-request/optic-neuritis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Optic Neuritis Market Report

• In 2024, an estimated 16,500 people in EU4 and the UK had incident cases of optic neuritis, highlighting not only a significant regional disease burden but also the growing need for earlier diagnosis, improved treatment options, and targeted strategies to prevent long-term vision impairment.
• In the US in 2024, optic neuritis incidence showed a marked sex disparity, with females accounting for nearly 15,000 new cases-almost double the approximately 8,000 cases reported in males-highlighting a pronounced gender-related incidence trend.
• In 2024, in the US, incident cases of optic neuritis were predominantly acute, with approximately 22,000 cases, compared to 1,150 chronic cases. This imbalance is expected to persist by 2034, reflecting the higher occurrence of sudden-onset inflammation compared to long-standing disease.
• In 2024, in Japan, incident cases of optic neuritis were highest among individuals aged 19-44 years, with approximately 550 cases, followed by 500 cases in those aged 45-64 years, 220 cases in those 65 years and above, and 40 cases in the 0-18 years group. This age distribution reflects a greater burden in early to mid-adulthood compared to pediatric and older populations.
• In the UK, an around 2,000 incident cases of optic neuritis in 2024 involved unilateral presentation, compared to nearly 500 bilateral cases, highlighting the predominance of single-eye involvement. Projections indicate a gradual rise in total case numbers by 2034.
• The leading Optic Neuritis Companies such as Oculis, Bio-Thera Solutions, Alexion Pharmaceuticals Inc., Amgen, Biocad, Hansoh BioMedical R&D Company, Beijing Mabworks Biotech Co., Ltd., Hoffmann-La Roche, RemeGen Co., Ltd., and others
• Promising Optic Neuritis Therapies such as Efgartigimod Alfa, OCS-05 IV administration, Ravulizumab, B001, Inebilizumab, Inebilizumab, Divozilimab, MIL62, Satralizumab, and others

Gain a competitive edge in the Optic Neuritis Market by exploring our in-depth analysis @ Optic Neuritis Treatment Drugs-- https://www.delveinsight.com/sample-request/optic-neuritis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Optic Neuritis Marketed Drugs

• KENKETSU VENILON-I (Immune globulin sulfonated human): KM Biologics/ TEIJIN LIMITED
KENKETSU VENILON-I is a sterile IV infusion formulation of human serum albumin designed for the treatment of patients requiring albumin replacement therapy. Delivered via a ready-to-use single-dose vial, each vial contains purified human serum albumin stabilized with sodium caprylate and N-acetyltryptophanate as excipients to ensure product stability and safety.

Optic Neuritis Emerging Drugs

• Privosegtor (OCS-05): Oculis
Privosegtor (OCS-05) is a novel oral small-molecule therapeutic designed to target neuroprotective pathways. It is formulated to optimize bioavailability and central nervous system penetration, enabling effective modulation of inflammatory and neurodegenerative processes. Privosegtor's molecular design supports sustained receptor engagement, aiming to provide prolonged therapeutic effects with a favorable safety profile. The formulation is engineered to enhance stability and absorption in the gastrointestinal tract, ensuring consistent systemic exposure. This innovative approach holds promise for treating conditions involving optic nerve inflammation and neurodegeneration. Privosegtor has received Orphan Drug Designation (ODD) by both the Food and Drug Administration (FDA) and the European Commission (EC) for acute optic neuritis.

Visit our website to access the full report and make informed strategic decisions @ https://www.delveinsight.com/sample-request/optic-neuritis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Optic Neuritis Drug Market Insights

The optic neuritis treatment landscape is evolving from primarily supportive care toward targeted, disease-modifying therapies (DMT) that focus on neuroprotection, inflammation reduction, and remyelination. Conventional approaches, such as corticosteroids and symptomatic management, provide limited long-term benefits, underscoring the urgent need for innovative treatments that can improve recovery and prevent disease progression. New drug classes with neuroprotective mechanisms are emerging to transform optic neuritis treatment. Currently, no US FDA approved therapies exist, but promising candidates like privosegtor (OCS-05) are under development. As a potential first-in-class neuroprotective agent, privosegtor aims to reduce inflammation and promote neural repair, signaling a shift toward targeted treatments that address the underlying pathology rather than just symptom management.

Optic Neuritis Emerging Drugs Profile
• OCS-05: Oculis
• ST266: Noveome Biotherapeutics

Discover key developments and opportunities in the Optic Neuritis Market. Click here to learn more from DelveInsight's latest report @ Optic Neuritis Market Size- https://www.delveinsight.com/sample-request/optic-neuritis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Optic Neuritis Drugs and Companies
• OCS-05 IV administration: Oculis
• BAT4406F Injection: Bio-Thera Solutions
• Ravulizumab: Alexion Pharmaceuticals
• B001: Shanghai Drug Research Development Co. Ltd.
• Inebilizumab: Hansoh BioMedical R&D Company

Optic Neuritis Market Access and Reimbursement

Optic neuritis is a complex and often disabling condition characterized by inflammation and demyelination of the optic nerve, leading to sudden vision loss and frequently serving as an early indicator of chronic neurodegenerative diseases such as multiple sclerosis. Despite advances in understanding the disease mechanisms, effective treatments that modify disease progression remain limited, and emerging neuroprotective therapies, while promising, often come with substantial costs. These financial barriers can significantly restrict patient access to potentially sight-saving treatments, resulting in delayed intervention and poorer long-term outcomes. Implementing a comprehensive reimbursement program is therefore critical-not only to reduce the direct economic burden on patients but also to encourage early diagnosis and sustained adherence to therapy.

Download DelveInsight's Optic Neuritis Market report today and stay ahead in this rapidly evolving field. @ Optic Neuritis Clinical Trials- https://www.delveinsight.com/sample-request/optic-neuritis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Optic Neuritis Market Report

• Coverage- 7MM
• Study Period- 2020-2034
• Optic Neuritis Companies- Oculis, Bio-Thera Solutions, Alexion Pharmaceuticals Inc., Amgen, Biocad, Hansoh BioMedical R&D Company, Beijing Mabworks Biotech Co., Ltd., Hoffmann-La Roche, RemeGen Co., Ltd, and others.
• Optic Neuritis Therapies-Efgartigimod Alfa, OCS-05 IV administration, Ravulizumab, B001, Inebilizumab, Inebilizumab, Divozilimab, MIL62, Satralizumab, and others
• Optic Neuritis Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
• Optic Neuritis Unmet Needs, KOL's views, Analyst's views, Optic Neuritis Market Access and Reimbursement

Download the report to understand which factors are driving Optic Neuritis market trends @ Optic Neuritis Market Trends- https://www.delveinsight.com/sample-request/optic-neuritis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content

1. Introduction
2. Optic Neuritis Executive Summary
3. Optic Neuritis: Overview
4. Optic Neuritis Pipeline Therapeutics
5. Optic Neuritis Therapeutic Assessment
6. Optic Neuritis- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Product Name: Company Name
9. Drug profiles in the detailed report.....
10. Mid Stage Products (Phase II)
11. OCS-05: Oculis
12. Drug profiles in the detailed report.....
13. Early Stage Products (Phase I)
14. Product Name: Company Name
15. Drug profiles in the detailed report.....
16. Preclinical and Discovery Stage Products
17. Product Name: Company Name
18. Drug profiles in the detailed report.....
19. Inactive Products
20. Optic Neuritis Companies
21. Optic Neuritis Products
22. Optic Neuritis Unmet Needs
23. Optic Neuritis Market Drivers and Barriers
24. Optic Neuritis- Future Perspectives and Conclusion
25. Optic Neuritis Analyst Views
26. Optic Neuritis Companies
27. Appendix

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

This release was published on openPR.